US 12,077,586 B2
Bispecific antibodies for use in the treatment of hematological malignancies
Iris De Weerdt, Utrecht (NL); Arnon Philip Kater, Utrecht (NL); Paul Willem Henri Ida Parren, Utrecht (NL); Tanja Denise De Gruijl, Utrecht (NL); Johannes Jelle Van Der Vliet, Utrecht (NL); and Roeland Lameris, Utrecht (NL)
Assigned to LAVA THERAPEUTICS N.V., Utrecht (NL)
Appl. No. 17/277,984
Filed by LAVA THERAPEUTICS N.V., Utrecht (NL)
PCT Filed Sep. 19, 2019, PCT No. PCT/NL2019/050625
§ 371(c)(1), (2) Date Mar. 19, 2021,
PCT Pub. No. WO2020/060406, PCT Pub. Date Jun. 26, 2020.
Claims priority of application No. 2021664 (NL), filed on Sep. 19, 2018.
Prior Publication US 2021/0371525 A1, Dec. 2, 2021
This patent is subject to a terminal disclaimer.
Int. Cl. C07K 16/28 (2006.01); A61K 39/395 (2006.01); A61P 35/00 (2006.01); A61P 35/02 (2006.01)
CPC C07K 16/2809 (2013.01) [A61K 39/3955 (2013.01); A61P 35/00 (2018.01); A61P 35/02 (2018.01); C07K 2317/22 (2013.01); C07K 2317/31 (2013.01); C07K 2317/565 (2013.01); C07K 2317/569 (2013.01); C07K 2317/73 (2013.01)] 13 Claims
OG exemplary drawing
 
1. A method of treating Chronic Lymphocytic Leukemia (CLL), Multiple Myeloma (MM), or Acute Myeloid Leukemia (AML) in a subject in need thereof comprising administering an antibody comprising
(a) a first binding moiety that is able to bind human CD1d and comprises a complementarity determining region (CDR)1 comprising the amino acid sequence of SEQ ID NO: 34, a CDR2 comprising the amino acid sequence of SEQ ID NO: 35, and a CDR3 sequences comprising the amino acid sequence of SEQ ID NO: 36; and
(b) a second binding moiety that is able to bind the human Vγ9Vδ2-TCR and comprises the amino acid sequence of SEQ ID NO: 162.